Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

439.82 +5.63 (+1.30%)
Streaming Delayed Price Updated: 12:23 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 598,268
Open 434.01
Bid (Size) 439.67 (200)
Ask (Size) 439.98 (320)
Prev. Close 434.19
Today's Range 430.66 - 441.23
52wk Range 362.50 - 519.68
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top Affordable Growth Stock ↗
Vertex Pharmaceuticals offers strong growth, solid profits, and a healthy balance sheet, all at a reasonable valuation compared to its biotech peers. 
Via Chartmill

Performance

YTD
+8.4%
+8.4%
1 Month
+8.0%
+8.0%
3 Month
+11.1%
+11.1%
6 Month
+4.4%
+4.4%
1 Year
-10.2%
-10.2%

More News

Read More
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Global Markets Brace for Inflation's Enduring Grip: A November 2025 Outlook
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗
Via Benzinga
News headline image
2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges
Via StockStory
News headline image
Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday? ↗
Via Benzinga
News headline image
VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook
Via StockStory
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations
Via StockStory
News headline image
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book ↗
Via Investor's Business Daily
News headline image
Vertex Reports Third Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
Via Benzinga
News headline image
Nvidia, Amazon Extend Rally, Bitcoin Sinks To $107,000: What's Moving Markets Monday? ↗
Via Benzinga
News headline image
2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years? ↗
Via The Motley Fool
Topics Economy Government World Trade
News headline image
My Top Growth Stock to Buy in November ↗
Via The Motley Fool
News headline image
Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect
Via StockStory
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
Via MarketBeat
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
News headline image
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These ↗
Via The Motley Fool

Frequently Asked Questions

Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 439.82
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 11/13/25 12:23 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 114.10B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 114B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.